<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04282148</url>
  </required_header>
  <id_info>
    <org_study_id>ABT-CIP-10321</org_study_id>
    <nct_id>NCT04282148</nct_id>
  </id_info>
  <brief_title>Abbott Next Generation Drug Eluting Stent 48mm Study</brief_title>
  <acronym>ABT NG DES 48</acronym>
  <official_title>A Clinical Investigation to Assess the Abbott Next Generation Drug Eluting Stent 48mm Everolimus Eluting Coronary Stent System (EECSS) in Treatment of de Novo Native Coronary Artery Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Medical Devices</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Medical Devices</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this ABT NG DES 48 study is to evaluate the safety and effectiveness of the
      ABT NG DES 48 EECSS in improving coronary artery luminal diameter in subjects with coronary
      artery disease (CAD) due to de novo native coronary artery long lesions.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 17, 2020</start_date>
  <completion_date type="Anticipated">June 2024</completion_date>
  <primary_completion_date type="Anticipated">November 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Target Lesion Failure (TLF)</measure>
    <time_frame>1 year</time_frame>
    <description>Target Lesion Failure (TLF) is defined as a composite of cardiac death, target vessel myocardial infarction [TV-MI] (MI is per modified Academic Research Consortium [ARC] definition), and clinically indicated target lesion revascularization [CI-TLR])</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Target Lesion Failure (TLF)</measure>
    <time_frame>In-hospital 6 to 12 hours post procedure</time_frame>
    <description>Target Lesion Failure (TLF) is defined as a composite of cardiac death, target vessel myocardial infarction [TV-MI] (MI is per modified Academic Research Consortium [ARC] definition), and clinically indicated target lesion revascularization [CI-TLR])</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Target Lesion Failure (TLF)</measure>
    <time_frame>30 days</time_frame>
    <description>Target Lesion Failure (TLF) is defined as a composite of cardiac death, target vessel myocardial infarction [TV-MI] (MI is per modified Academic Research Consortium [ARC] definition), and clinically indicated target lesion revascularization [CI-TLR])</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Target Lesion Failure (TLF)</measure>
    <time_frame>180 days</time_frame>
    <description>Target Lesion Failure (TLF) is defined as a composite of cardiac death, target vessel myocardial infarction [TV-MI] (MI is per modified Academic Research Consortium [ARC] definition), and clinically indicated target lesion revascularization [CI-TLR])</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Target Lesion Failure (TLF)</measure>
    <time_frame>2 years</time_frame>
    <description>Target Lesion Failure (TLF) is defined as a composite of cardiac death, target vessel myocardial infarction [TV-MI] (MI is per modified Academic Research Consortium [ARC] definition), and clinically indicated target lesion revascularization [CI-TLR])</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>ABT NG DES 48 EECSS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive ABT NG DES 48 EECSS device</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ABT NG DES 48 EECSS</intervention_name>
    <description>Each participant will receive ABT NG DES 48 EECSS with appropriate diameter</description>
    <arm_group_label>ABT NG DES 48 EECSS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        General Inclusion Criteria:

          1. Subject must be at least 18 years of age.

          2. Subject or a legally authorized representative must provide written informed consent
             prior to any study related procedure, per site requirements.

          3. Subject must have evidence of myocardial ischemia (e.g., unstable angina, post-infarct
             angina, stable angina or silent ischemia) suitable for non-emergent PCI. Subject with
             stable angina or silent ischemia must have objective sign of ischemia as determined by
             one of the following,

               -  Abnormal stress or imaging stress test,

               -  Abnormal computed tomography-fractional flow reserve (CT-FFR)

               -  Stenosis by visual estimation ≥ 70%

               -  Abnormal pressure-derived indexes (FFR, instantaneous wave-free ratio [iFR], or
                  relative flow reserve [RFR]).

          4. Subject must be an acceptable candidate for coronary artery bypass graft (CABG)
             surgery.

          5. Subject must agree not to participate in any other clinical study for a period of one
             year following the index procedure.

        Angiographic Inclusion Criteria:

          1. Only one de novo target lesion in native coronary artery is allowed to be treated with
             the investigational stent.

             • One additional non-target lesion can be treated if it is located in a different
             epicardial coronary vessel and NOT in left main coronary artery. The Non-target lesion
             must be treated first and must be deemed an angiographic success.

          2. The target lesion must be located in a native coronary artery with:

               -  Visually estimated reference vessel diameter (RVD) of ≥ 2.5 mm and ≤ 4.25 mm.

               -  Visually estimated lesion length of &gt; 32 mm and ≤ 44 mm, and able to be covered
                  by a single ABT NG DES 48.

                  a. Multiple focal de novo lesions in an epicardial coronary vessel are allowed if
                  the lesions can be covered by one stent. Multiple focal de novo lesions will be
                  counted as a single lesion.

               -  Visually estimated diameter stenosis of &gt; 50% and &lt; 100% with a Thrombolysis in
                  Myocardial Infarction (TIMI) flow of ≥ 1.

                    -  Stable angina or silent ischemia subjects must have stenosis ≥ 70%, or
                       abnormal pressure-derived physiological indices (FFR, iFR, or RFR), unless
                       abnormal stress or imaging stress test is evidenced

        Exclusion Criteria:

        General Exclusion Criteria:

          1. Subject has known hypersensitivity or contraindication to device material and its
             degradants (everolimus, cobalt, chromium, nickel, tungsten, acrylic and
             fluoropolymers, etc.), or has known contrast sensitivity.

          2. Subject has known hypersensitivity or contraindication to aspirin,
             heparin/bivalirudin, P2Y12 inhibitors (clopidogrel /prasugrel /ticagrelor), and
             therefore cannot be adequately pre-medicated.

          3. Subject has a planned surgery or procedure necessitating discontinuation of aspirin or
             P2Y12 inhibitor within 12 months following index procedure.

          4. Subject is receiving or will require chronic anticoagulation therapy (e.g., coumadin,
             dabigatran, apixaban, rivaroxaban or any other agent for any reason).

          5. Pregnant or nursing subjects and those who plan pregnancy in the period up to 1 year
             following index procedure. Female subjects of child-bearing potential must have a
             negative pregnancy test done within 7 days prior to the index procedure per site
             standard test.

          6. Subject had an acute myocardial infarction (AMI) within 48 hours of the index
             procedure with either of the situations below:

               -  The subject is currently experiencing clinical symptoms consistent with new onset
                  AMI, such as nitrate-unresponsive prolonged chest pain with ischemic
                  electrocardiogram (ECG) changes

               -  Elevated cardiac enzyme values have not returned to within normal limits at the
                  time of index procedure.

          7. Subject has a left ventricular ejection fraction (LVEF) &lt; 30% within 3 months prior to
             the index procedure, that was documented by any method.

          8. Subject is expected to require percutaneous mechanical cardiac support at the index
             procedure.

          9. Prior PCI within the target vessel during the last 12 months prior to consent.

         10. Prior PCI within the non-target vessel or any peripheral intervention during the last
             30 days prior to consent.

         11. At the index procedure, subject is identified to require planned stenting procedure
             (including staged procedures) or CABG after the index procedure.

         12. Subject has received a solid organ transplant which is functioning or is active on a
             waiting list for any solid organ transplants with expected transplantation within 24
             months.

         13. Subject has a malignancy that is not in remission.

         14. Subject is receiving immunosuppressant therapy or has known life-threatening
             immunosuppressive or severe autoimmune disease (e.g., human immunodeficiency virus,
             systemic lupus erythematosus, etc.). Note: corticosteroids are not included as
             immunosuppressant therapy, diabetes mellitus is not regarded as autoimmune disease

         15. Subject has previously received or is scheduled to receive radiotherapy to a coronary
             artery (vascular brachytherapy), or the chest/mediastinum.

         16. Subject has a platelet count &lt; 100,000 cells/mm3 or &gt; 700,000 cells/mm^3.

         17. Subject has renal insufficiency as defined as an estimated glomerular filtration rate
             (GFR) &lt; 30 ml/min/1.73m^2 or dialysis at the time of consent.

         18. Subject is high risk of bleeding for any reason; has a history of bleeding diathesis
             or coagulopathy; has had a significant gastro-intestinal or significant urinary bleed
             within the past six months.

         19. Subject has had a cerebrovascular accident or transient ischemic neurological attack
             (TIA) within the past 6 months, or any prior intracranial bleed, or any permanent
             neurologic defect, or any known intracranial pathology (e.g. aneurysm, arteriovenous
             malformation, etc.).

         20. Subject has extensive peripheral vascular disease that precludes safe 6 French sheath
             insertion. Note: femoral arterial disease does not exclude the subject if radial
             access may be used.

         21. Subject has life expectancy &lt; 2 years.

         22. Subject is, in the opinion of the Investigator or designee, unable to comply with the
             requirements of the study protocol or is unsuitable for the study for any reason. This
             includes completion of Subject Reported Outcome instruments.

         23. Subject is currently participating in another clinical investigation (except for
             non-invasive observational studies) that has not yet completed its primary endpoint.

         24. Subject intends to participate in another investigational drug or device clinical
             investigation (except for non-invasive observational studies) within 12 months after
             the index procedure.

         25. Subject has other medical illness (e.g., cancer or congestive heart failure) or known
             history of substance abuse (alcohol, cocaine, heroin etc.) that may cause
             non-compliance with the protocol, confound the data interpretation or is associated
             with a limited life expectancy less than 1 year.

         26. Presence of other anatomic or comorbid conditions, or other medical, social, or
             psychological conditions that, in the investigator's opinion, could limit the
             subject's ability to participate in the clinical investigation or to comply with
             follow-up requirements, or impact the scientific soundness of the clinical
             investigation results.

        Angiographic Exclusion Criteria:

          1. Target lesion/vessel meets any of the following criteria;

               -  Prevents complete angioplasty balloon (plain old balloon angioplasty [POBA],
                  scoring balloon, or cutting balloon) inflation, such as:

                    -  Heavy calcified lesion

                    -  Requires additional device for lesion preparation (e.g. rotablator or
                       laser).

               -  Anatomy proximal to or within the lesion that prevents proper placement of
                  delivery system.

                    -  Extreme angulation (≥ 90°) proximal to or within the target lesion.

                    -  Excessive tortuosity (≥ two 45° angles) proximal to or within the target
                       lesion.

               -  Involves a bifurcation of which the side branch will be jailed by the struts and
                  requiring side branch pre-dilatation (including Kissing Balloon Technique),
                  and/or stenting

               -  Is located:

                    -  In left main or there is a ≥30% diameter stenosis in the left main (unless
                       the left main lesion is a protected left main (i.e. a patent bypass graft to
                       the left anterior descending coronary artery [LAD] and/or left circumflex
                       coronary artery [LCX] arteries is present), and there is no intention to
                       treat the protected left main lesion).

                    -  Within 3 mm of the origin of the LAD or LCX.

                    -  Within 3 mm of aorto-ostial right coronary artery (RCA).

                    -  In a bypass graft or distal to anastomotic site of bypass graft.

               -  With total occlusion (TIMI flow 0), prior to crossing with the wire.

               -  Contains thrombus

               -  Has been previously treated with a stent at any time prior to the index procedure
                  such that the ABT NG DES 48 would need to cross the stent to reach the target
                  lesion.

          2. Unsuccessful target lesion pre-dilatation, defined as the presence of one or more of
             the following:

               -  Residual % diameter stenosis (DS) after pre-dilatation is ≥ 40% (per visual
                  estimation).

               -  TIMI flow grade &lt;3 (per visual estimation).

               -  Any angiographic complication (e.g. distal embolization, no-reflow)

               -  Any dissection National Heart, Lung, and Blood Institute (NHLBI) grade D-F.

               -  Any chest pain lasting &gt; 5 minutes.

               -  Any ST-segment depression or elevation lasting &gt; 5 minutes.

               -  Side branch requires additional dilatation/stenting caused by plaque shift,
                  carina shift or may require additional dilatation/stenting after stent
                  implantation, per the operator's assessment.

          3. Non-target lesion meets any of the following criteria:

               -  Is located in the target vessel

               -  Is located in the left main location

               -  Is restenotic from a previous stent implantation

               -  Is located within a saphenous vein graft or an arterial graft

               -  Is with a TIMI flow 0 (total occlusion) prior to guide wire crossing

               -  Involves a complex bifurcation that needs two-stent strategy.

          4. Treatment of non-target lesion is not deemed successful. Note: A successful treatment
             is defined as a treatment resulted in a mean lesion diameter stenosis &lt; 30% in 2
             near-orthogonal projections with TIMI 3 flow, as visually assessed by the physician,
             without the occurrence of prolonged chest pain or ECG changes consistent with MI.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mariah Tackett</last_name>
    <role>Study Director</role>
    <affiliation>Abbott</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Steve Peck</last_name>
    <phone>9725269665</phone>
    <email>steven.peck@abbott.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lijuan Jenny Wang, PHD</last_name>
    <phone>4088453133</phone>
    <email>lijuan.wang1@abbott.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cardiovascular Research Institute of Kansas</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amber Korbe</last_name>
      <email>amber.korbe@cckheart.com</email>
    </contact>
    <investigator>
      <last_name>Aziz Maksoud, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>February 18, 2020</study_first_submitted>
  <study_first_submitted_qc>February 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 24, 2020</study_first_posted>
  <last_update_submitted>June 22, 2020</last_update_submitted>
  <last_update_submitted_qc>June 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>De novo native coronary artery long lesions</keyword>
  <keyword>ABT NG DES 48 EECSS</keyword>
  <keyword>ABT-CIP-10321</keyword>
  <keyword>Coronary artery luminal diameter</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

